Launchpad Therapeutics

Developer of early mutant selective antibody intended to support drug design for cancer therapies The company uses artificial intelligence-driven programs to deliver novel monoclonal antibodies with drug design, development, and testing for research, providing medical professionals with alternative ways of cancer treatment.

New Enterprise Associates